Global leaders in FeNO testing
Our mission

To improve asthma diagnosis & management by greater patient access to FeNO testing.
Asthma

- One of the **biggest healthcare problems** in the world
- There are over **340 million** asthma sufferers worldwide
- Asthma causes the **loss of 1,000 lives every day**, with the consequences felt worldwide
- More than **200 million** patients are **at risk of an asthma attack** every year
- Over **60%** of patients have **uncontrolled** symptoms
- Improving asthma control **saves significant medical costs**
The Company and its technology

- NIOX Group plc is listed on London’s AIM market

- The Company’s market leading product NIOX VERO® uses patented technology to accurately measure Fractional exhaled Nitric Oxide (FeNO) @ ppb level

- The role that Nitric Oxide (NO) plays in asthma diagnosis was discovered in the 1990’s and established in international guidelines in 2005.

- NIOX VERO® is registered and reimbursed in all major markets and available in more than 50 countries

- NIOX VERO® is the device of choice for both Clinical and Research use.
At the forefront of innovation for 24 years

1998: NIOX®
2003: NIOX FLEX®
2008: NIOX MINO®
2011: ATS guidelines 83% of patients tested on NIOX®
2013: NIOX VERO®
2017: Nasal NO developed for NIOX VERO®, 40 million
2021: 45 million
2022: ERS, 40 million tests worldwide. A true milestone for patients.
Why FeNO testing?

- Fraction of exhaled Nitric Oxide (FeNO) is a **precise biomarker** for asthma
- Asthma is **not diagnosed** or is **mis-diagnosed** in up to 50% of patients
- A FeNO test provides a **7x greater chance of a correct diagnosis**
- A measurement of FeNO is **quick, easy and non-invasive**
- Regular FeNO testing can **predict** and **help prevent** exacerbations by 50%
Strong scientific and health economic support for FeNO testing
NIOX®: The market leader

- The market leader, authorised in most major markets and available in over 50 countries
- NIOX® owns a significant IP portfolio
- NIOX VERO® is the most accurate and reproducible FeNO device on the market
- First choice for healthcare professionals (HCP) with nearly 45 million tests to date
- Thousands of NIOX® devices are in daily use by HCP and in clinical trials
- Portable and easy to use with real-time results
Improving patient access to FeNO testing

The global trend is to **shift healthcare out of clinical settings** and into the home - COVID accelerated this.

The vast **majority of asthmatics are treated in Primary Care / pharmacy settings today.**

In the future **personal FeNO devices** will lead to **better management** of asthma and reductions in healthcare costs.

NIOX VERO®
Secondary Care
Hospitals and respiratory centres

NIOX VERO®
Primary Care
General Practice (GPs) and asthma clinics.
Followed by pharmacy

Future Device
Home / personal
FeNO testing
NIOX® latest awards

2022 Marketing & Advertising Today Award

2022 Research & Development Award

Healthcare and Pharmaceutical Awards - Global Leaders in FeNO Testing 2021

Healthcare and Pharmaceutical Awards - Most Innovative Asthma Management Technology 2021

Dedicated to point of care asthma diagnosis and management